An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

THE LAWSUIT: A class action securities lawsuit was filed against Applied Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American ...

James George Chopas, Vice President and Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), sold 1,096 shares of the company's common stock on January 22, according to a recent ...

Malawi breaking news publishing 24 hours a day news about Malawi, Malawi Business, Malawi Tourism, Malawi Politics, Malawi News ...

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.